N. Shah

发表

Patient Preferences for Preventive Migraine Treatments: A Discrete‐Choice Experiment

C. Mansfield, S. Tepper, T. Schwedt, 2019, Headache.

Factors Associated with Direct Health Care Costs Among Patients with Migraine.

K. Widnell, P. Winner, M. Bonafede, 2017, Journal of managed care & specialty pharmacy.

Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study

G. Deshpande, N. Shah, T. Gu, 2016, Drugs - Real World Outcomes.

Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice

G. Lyman, L. Lamerato, K. Richert-Boe, 2020, Supportive Care in Cancer.

Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective

R. Lipton, A. Brennan, S. Palmer, 2018, Journal of medical economics.

Treatment Patterns and Annual Drug Costs of Biologic Therapies Across Indications from the Humana Commercial Database

D. Harrison, R. Dufour, N. Shah, 2014, Journal of managed care & specialty pharmacy.

Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.

D. Harrison, Yuan-chi Lee, N. Shah, 2014, Clinical therapeutics.

Effectiveness and costs of biologics in veterans with rheumatoid arthritis

J. Curtis, D. Harrison, B. Sauer, 2015 .

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population

M. Bonafede, D. Harrison, G. Joseph, 2014, ClinicoEconomics and outcomes research : CEOR.

Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

D. Dodick, S. Tepper, T. Wilcox, 2021, Headache.

Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States

M. Bonafede, S. Tepper, S. Sapra, 2018, Headache.

Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis

M. Bonafede, D. Harrison, N. Princic, 2015, Journal of medical economics.

Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study

D. Harrison, G. Deshpande, N. Shah, 2015 .

Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context

D. Harrison, N. Shah, N. Wu, 2015, ClinicoEconomics and outcomes research : CEOR.

Original article Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis

M. Bonafede, D. Harrison, N. Princic, 2015 .

Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.

M. Bonafede, D. Harrison, B. Stolshek, 2018, The American journal of managed care.

Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis

J. Walsh, D. Harrison, B. Sauer, 2016, Journal of medical economics.

Etanercept‐Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis

D. Collier, M. Bonafede, D. Harrison, 2015, Arthritis care & research.